The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The characteristics of ARID1A mutations in colorectal cancer.
 
Amir Mehrvarz Sarshekeh
No Relationships to Disclose
 
Jonathan M. Loree
No Relationships to Disclose
 
Ganiraju C. Manyam
No Relationships to Disclose
 
Allan Andresson Lima Pereira
No Relationships to Disclose
 
Kanwal Pratap Singh Raghav
Consulting or Advisory Role - Bayer (Inst); Genentech (Inst)
Travel, Accommodations, Expenses - TRACON Pharma
 
Michael Lam
No Relationships to Disclose
 
Jennifer S Davis
No Relationships to Disclose
 
A. Dasari
No Relationships to Disclose
 
Van Karlyle Morris
Consulting or Advisory Role - Clinical Genomics
Travel, Accommodations, Expenses - Array BioPharma
 
David Menter
No Relationships to Disclose
 
Cathy Eng
Honoraria - Bayer; Celgene; Roche; Sirtex Medical
Consulting or Advisory Role - Bayer Schering Pharma; Roche/Genentech; Taiho Pharmaceutical
Research Funding - Advaxis; Forty Seven; Genentech/Roche; Keryx
Travel, Accommodations, Expenses - Bayer; Genentech/Roche; Sirtex Medical
 
Russell Broaddus
No Relationships to Disclose
 
Mark Routbort
No Relationships to Disclose
 
Rajyalakshmi Luthra
No Relationships to Disclose
 
Dipen M. Maru
No Relationships to Disclose
 
Michael J. Overman
Consulting or Advisory Role - Bristol-Myers Squibb; Merrimack; Roche/Genentech
Research Funding - Amgen; Bristol-Myers Squibb; Celgene; MedImmune; Merck; Roche
 
Funda Meric-Bernstam
Honoraria - Dialectica; Sumitomo Group
Consulting or Advisory Role - Clearlight Diagnostics; DarwinHealth; Genentech; GRAIL; Inflection Biosciences; Pieris Pharmaceuticals; Samsung Bioepis
Research Funding - Abbvie; Aileron Therapeutics; AstraZeneca; Bayer; Calithera Biosciences; Curis; CytomX Therapeutics; Debiopharm Group; eFFECTOR Therapeutics; Genentech; Jounce Therapeutics; Novartis; Pfizer; PUMA Biotechnology; Taiho Pharmaceutical; Zymeworks
 
Scott Kopetz
Stock and Other Ownership Interests - MolecularMatch; Navire
Consulting or Advisory Role - Amgen; Array BioPharma; Bayer; EMD Serono; Genentech; Guardant Health (Inst); Karyopharm Therapeutics; Merck; Roche; Symphony Evolution
Research Funding - Amgen (Inst); Array BioPharma (Inst); Biocartis (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Guardant Health (Inst); MedImmune (Inst); Novartis (Inst); Sanofi (Inst)